BofA cuts Hims and Hers stock price target on EBITDA concerns

BofA cut its price target on Hims & Hers to $21 from $23 and warns its 2026 EBITDA forecast sits ~21% below Street consensus, reducing its CY26 EV/EBITDA target to ~21.5x (from 23x). The firm expects GLP-1 EBITDA contributions could fall ~50% this year even as Hims adds Novo Nordisk GLP-1s and launches a $149/month subscription; the stock is down 66% over six months, trading at $19.50 (market cap $4.44B, EV/EBITDA ~26.4x). An insider (CFO) filed to sell 240,560 shares (~$4.9M) with a proposed sale date of April 6, 2026, while recent partnership news has driven a short-term rally.

Analysis

Telehealth platforms migrating from compounding/white‑label GLP‑1 fulfillment to branded product distribution create a bifurcation: companies that secure preferred economics from manufacturers gain defensible gross margin tailwinds over 12–36 months, while mid‑tier vertically integrated players face a near‑term margin squeeze as legacy inventory, fulfillment tech and marketing need repurposing. The structural lever is COGS per Rx — a 10–20% realized improvement in branded drug procurement scales straight to EBITDA and can compress time to breakeven by 6–12 months given subscription unit economics.

Near‑term downside risks concentrate in demand elasticity and multiple compression: if take rates fall 15–25% versus management plans the fix is not operational but economic, producing outsized EBITDA misses in the next 2–6 quarters because customer acquisition cost is mostly sunk. Regulatory/payer noise or supply squeezes from manufacturers can flip a re‑rate into a longer correction; conversely, clean monthly subs and improving gross margin per Rx are high‑conviction positive catalysts within two reporting cycles.

From a competitive standpoint, incumbents with deep CRM and multi‑category cross‑sell (mental health, dermatology, sexual health) are best positioned to monetize lifetime value beyond GLP‑1; smaller pure‑play competitors will see CAC reprice upward. Second‑order beneficiaries include specialty pharmacies and contract manufacturers who pick up volume, while payers and PBMs gain leverage if branded penetration rises and net prices stabilize.

The consensus risk is asymmetry: the market is pricing headline execution risk but underweights optionality from international rollouts and branded cost declines. A disciplined, binary play that sizes exposure to execution milestones (subscriber retention, gross margin per branded Rx, international ARPU) captures upside without overpaying for headline narrative that can reverse quickly on a single strong quarter.

Key Decisions for Investors

• Pair trade (6–12 months): Short HIMS equity (size 2–4% book) vs Long NVO equity (size 1–2% book) — target asymmetric payoff where HIMS down 30–50% funds NVO upside ~15–25%. Stop HIMS at 15–20% adverse move; trim NVO on +20% move.
• Options hedge (3–9 months): Buy HIMS 6–12 month put spread (limit premium) funded by selling a small number of out‑of‑the‑money calls to cap carry — scenario payoff if subscriber/stickiness metrics disappoint; keep max loss defined and theta positive on sold calls.
• Event‑driven long (12–24 months): Buy NVO call spread to express secular branded GLP‑1 pricing power and international scale; this reduces capital at risk versus outright stock and benefits from continued branded adoption and margin expansion.
• Tactical opportunistic trade (weeks–months): If HIMS reports improving gross margin per GLP‑1 Rx or better‑than‑feared churn, rotate partial short into a covered call write or buy a tight call spread to capture a fast re‑rate; if not, add to short position on the miss.
• Risk management: Monitor three triggers weekly — (1) monthly subscription churn and net adds, (2) reported gross margin per GLP‑1 Rx, (3) international ARPU; breach of any two conservatively sized triggers to the downside should increase short sizing by 50%.